PUBLISHER: Polaris Market Research | PRODUCT CODE: 1449486
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1449486
The global intensity-modulated radiotherapy market size is expected to reach USD 2.59 billion by 2032, according to a new study by Polaris Market Research. The report "Intensity Modulated Radiotherapy Market Share, Size, Trends, Industry Analysis Report, By Radiation Type (Proton radiation, Electron radiation, Photon radiation, Carbon-ion radiation); By Application; By End User; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The growth of the intensity-modulated radiotherapy (IMR) market is influenced by the rising prevalence of cancer cases, primarily breast, lung, and prostate cancers, in the global population. The higher effectiveness of providing customized radiation to the target area or the body infected by cancer without harming the healthy tissues is gaining utility in the healthcare space.
The technological advancements in the healthcare segment and ongoing research activities exploring the benefits of cancer treatments, including chemotherapy, surgery, and radiotherapy, are expected to show significant growth potential in the coming years. The evolution of combination therapies, such as chemoradiotherapy, is likely to necessitate the need for intensity-modulated radiotherapy in the marketplace.
The ongoing development of advanced radiation therapies in the marketplace is projected to drive new growth opportunities, according to the intensity-modulated radiotherapy market analysis. The Institute of Cancer Research and the Royal Marsden developed dysphagia-optimized IMR. Based on the 2023 study published in the Lancet, the DO-IMRT enhanced swallowing function among patients compared to the standard IMRT, making it a compatible treatment option for treating pharyngeal cancers.
The development of advanced radiation therapies in the marketplace by the researchers is projected to drive new growth opportunities, according to the intensity modulated radiotherapy market analysis. The institute of cancer research and the royal Marsden developed dysphagia-optimized IMR. Based on the 2023 study published in the Lancet, the DO-IMRT enhanced the swallowing function among patients compared to the standard IMRT, making it a compatible treatment option for treating pharyngeal cancers.
Moreover, the government and non-government agencies' profound interest in developing radiotherapy equipment in the required areas is likely to support market growth. For instance, the International Atomic Energy Agency initiated a new scheme, Ray of Hope, to enhance the accessibility of cancer care around the world by assisting in the adoption of radiotherapy machines and promoting training for healthcare providers.
Proton radiation segment is anticipated to witness the highest growth in the coming years due to its potential to offer safety to healthy tissue and elimination of cancer cells.
Brain cancer segment accounted for the largest market share owing to the growing number of brain cancer cases and the interest of patients towards non-invasive treatment.
Hospitals segment is projected to experience a larger revenue share due to the necessity for advanced healthcare infrastructure containing instruments such as x-rays and IMRT.
Asia Pacific is projected to register the fastest growth during the forecast period, attributable to the rising government initiatives in promoting cancer care.
The global players include Accuray Incorporated, Brainlab AG, Elekta AB, Hitachi, Ltd., IBA Dosimetry, Mevion Medical Systems, Mitsubishi Electric Corporation, and others.
Polaris Market Research has segmented the intensity-modulated radiotherapy market report based on radiation type, application, end-user and region: